慢性肾脏病与透析房颤患者使用直接口服抗凝药的系统评价
该系统评价检索至2017年,纳入10项研究,比较DOAC与华法林或阿司匹林在CKD和透析房颤患者中的卒中和出血结局,发现不同DOAC在中度CKD和血透患者中的疗效与出血风险存在差异,临床需权衡卒中与出血风险。
要点
- 中度CKD患者中,达比加群150mg每日两次和阿哌沙班较华法林显著降低卒中或系统性栓塞风险。
- 依度沙班和阿哌沙班与华法林相比大出血事件减少,利伐沙班和达比加群110mg无显著差异。
- 血透患者中利伐沙班和达比加群大出血风险增加,阿哌沙班与华法林无显著差异。
核心结论
- 临床医生在CKD和透析房颤患者中处方DOAC前应继续权衡卒中与出血风险。
研究设计与样本
- 系统评价纳入随机对照试验、队列研究和病例系列,检索1946年至2017年电子数据库,共纳入10项研究。
主要发现
- 中度CKD患者中,达比加群110mg、利伐沙班和依度沙班与华法林相比卒中结局无差异(HR分别为0.78,95%CI 0.51-1.21;0.82-0.84,95%CI 0.25-2.69;0.87,95%CI 0.65-1.18)。
- 中度CKD患者中,达比加群150mg每日两次和阿哌沙班较华法林显著降低卒中或系统性栓塞风险(HR 0.55,95%CI 0.34-0.89和HR 0.61,95%CI 0.39-0.94)。
- 中度CKD患者中,依度沙班和阿哌沙班与华法林相比大出血事件减少(HR 0.50-0.76),利伐沙班和达比加群110mg及150mg无显著差异。
- 血透患者中,阿哌沙班、达比加群(RR 1.71,95%CI 0.97-2.99)或利伐沙班(RR 1.8,95%CI 0.89-3.64)与华法林相比卒中结局无差异。
- 血透患者中,利伐沙班和达比加群与华法林相比大出血风险增加(RR 1.45-1.76),阿哌沙班与华法林相比无大出血差异。
临床怎么用
- 中度CKD房颤患者可考虑达比加群150mg每日两次或阿哌沙班以降低卒中风险,但需评估出血风险。
- 血透房颤患者使用利伐沙班或达比加群需警惕大出血风险增加,阿哌沙班可能出血风险较低。
局限性
- 10项纳入研究在大出血和卒中的定义上存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a lack of clear benefit and a potential risk of bleeding with direct oral anticoagulant (DOAC) use in chronic kidney disease (CKD) and dialysis patients with atrial fibrillation. The objective of this study was to evaluate how treatment with DOACs affects stroke and bleeding outcomes compared with warfarin or aspirin. METHODS: We conducted a systematic review of randomized controlled trials, cohort studies and case series, and searched electronic databases from 1946 to 2017. Studies evaluating stroke and bleeding outcomes with DOAC use in CKD and dialysis patients were included. RESULTS: From 8008 studies, 10 met the inclusion criteria. For moderate CKD patients (estimated glomerular filtration rate <60 mL/min/1.73 m2), there was no difference in stroke outcomes between dabigatran 110 mg [hazard ratio (HR) 0.78, 95% confidence interval (95% CI) 0.51-1.21], rivaroxaban (HR 0.82-0.84, 95% CI 0.25-2.69) and edoxaban (HR 0.87, 95% CI 0.65-1.18) versus warfarin. Dabigatran (150 mg twice daily) and apixaban reduced risk of stroke or systemic embolism significantly more than warfarin for moderate CKD patients (HR 0.55, 95% CI 0.34-0.89 and HR 0.61, 95% CI 0.39-0.94, respectively). Edoxaban and apixaban were associated with reduced major bleeding events (HR 0.50-0.76) compared with warfarin. Rivaroxaban and dabigatran 110 mg and 150 mg showed no significant difference in major bleeding versus warfarin. In hemodialysis (HD) patients, there was no difference in stroke outcomes between apixaban, dabigatran [relative risk (RR) 1.71, 95% CI 0.97-2.99] or rivaroxaban (RR 1.8, 95% CI 0.89-3.64) versus warfarin. In HD patients, rivaroxaban and dabigatran were associated with an increased major bleeding risk (RR 1.45-1.76), whereas there was no major bleeding difference with apixaban compared to warfarin. LIMITATIONS: The heterogeneity of major bleeding and stroke definitions of the 10 included studies. CONCLUSIONS: Clinicians should continue to weigh the risk of stroke versus bleeding before prescribing DOACs in the CKD and dialysis population.
引用
- Feldberg J, Patel P, Farrell A, et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2019. PMID: 29509922. doi:10.1093/ndt/gfy031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。